Related Experiment Video
Updated: Sep 21, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Vandetanib-Induced Hyponatremia and Torsades De Pointes: A Case Report
Shoaib Ashraf1, Niel Shah1, Muhammad Saad2
1Internal Medicine, BronxCare Health System/Icahn School of Medicine at Mount Sinai, New York City, USA.
Abstract:
Medullary thyroid cancer (MTC) is a neuroendocrine tumor of the parafollicular cells of the thyroid gland. The prognosis is very poor in patients with advanced MTC. Vandetanib was approved for advanced MTC after randomized control trials showed that it had therapeutic efficacy and considerably prolonged progression-free survival. Vandetanib therapy is associated with serious cardiovascular side effects including hypertensive crisis and arrhythmias due to prolonged QTc. We present a case of an 83-year-old female with advanced metastatic MTC who is under treatment with vandetanib 300 mg/day and developed medication-related hyponatremia, QTc prolongation, ventricular fibrillation (VF), and torsades de pointes (TdP). Her vandetanib therapy was held. Subsequently, she did not show recurrences of TdP. This is the second such case report in the literature.
Insights
This case report details a patient with advanced medullary thyroid cancer (MTC) who experienced severe cardiac events, including Torsades de Pointes, while on Vandetanib. Discontinuation of Vandetanib resolved these dangerous arrhythmias.
Area of Science:
- Endocrinology
- Oncology
- Cardiology
Background:
- Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor with a poor prognosis in advanced stages.
- Vandetanib is approved for advanced MTC, demonstrating efficacy in prolonging progression-free survival.
- Vandetanib carries risks of serious cardiovascular side effects, including QTc prolongation and arrhythmias.
Observation:
- An 83-year-old female with metastatic MTC developed hyponatremia and QTc prolongation during Vandetanib treatment.
- The patient experienced ventricular fibrillation and Torsades de Pointes (TdP), a life-threatening arrhythmia.
- These adverse events occurred while on Vandetanib 300 mg/day.
Findings:
- Discontinuation of Vandetanib therapy led to the resolution of Torsades de Pointes.
- This case highlights a potential link between Vandetanib, hyponatremia, and severe cardiac arrhythmias.
- This is the second reported case of Vandetanib-induced Torsades de Pointes in medullary thyroid cancer patients.
Implications:
- Clinicians should closely monitor patients on Vandetanib for electrolyte imbalances and QTc prolongation.
- Vigilance for cardiac arrhythmias like TdP is crucial in patients with advanced MTC treated with Vandetanib.
- This case underscores the importance of risk-benefit assessment and careful patient selection for Vandetanib therapy.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Thiazide-Class Diuretics
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Disorder of Water Balance
Dehydration
Dehydration occurs when the body loses fluids (particularly water).
Causes:
The major causes of dehydration include excessive sweating, fever, vomiting, diarrhea, and diuresis.
Signs and Symptoms:
Symptoms primarily include intense...
Regulation of Water Intake

